logo
Search
Close this search box.
Schedule a Meeting
Search
Close this search box.

Avoidance of Inappropriate De-escalation with T2Candida

Case study highlighting the rapid identification of Candida infection while cultures remained negative

Gulf Coast Medical Center, Lee Health | Fort Meyers, FL

 

Presentation

A 75-year-old female presenting with abdominal pain and hypotension.

Patient History

Hypertension, hyperlipidemia, type 2 Diabetes mellites, ovarian cancer with metastases, placement of a percutaneous endoscopic gastrostomy (PEG) tube, and total parental nutrition (TPN) dependent. 

The patient was recently discharged after a prolonged hospital stay (3 weeks) and underwent several GI surgeries, most recently a bowel resection for duodenal perforation as a result of tumor erosion.

Surgical oncology, Gastroenterology, and Infectious Diseases services were all consulted to manage the case.

Evaluation and Treatment Decision

  • Urinalysis was positive for many yeast on the admission workup
  • Blood and urine cultures and T2Candida were ordered by ID consultant
  • T2Candida was positive for Candida glabrata/krusei, while blood and urine cultures remained negative
  • The patient was initiated on Piperacillin/Tazobactam and Micafungin

The identification of Candida glabrata/krusei with the T2Candida Panel prevented the inappropriate de-escalation of antifungal therapy in a high-risk patient.

Learn More

To learn more about T2Candida and this case study, watch the webinar, Real World Experience with T2Candida at a Community Health System
Watch Webinar

1. Chandler, E. Real World Experience with T2Candida at a Community Health System (Webinar). 2024

According to the CDC, of the 154 million prescriptions for antibiotics written in doctors’ offices and emergency departments each year, 30% are unnecessary.12

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER

SITEMAP

FOLLOW US ON SOCIAL

Linkedin-in Twitter

Please tell us where you are visiting from: United States | Outside the United States